Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

RSV: experts explain why rates of this virus are surging this year

Respiratory syncytial virus (RSV) is a very common virus, typically causing infection in children during the colder months. In most cases, RSV causes a mild illness, with symptoms similar to that of a regular cold.

The Conversation

Morningstar Lists Undervalued Stocks with Strong Profits

As of Nov. 11, just 29% of Morningstar-covered stocks that reported Q3 earnings beat estimates by at least 10%.

The Street

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads

Eli Lilly reportedly is pulling advertising from Twitter after a fake account promised free insulin in a fiasco that depressed LLY stock.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Independent UK

Eli Lilly Dives After Fake Twitter Account Promises Free Insulin; Takes Novo Nordisk, Sanofi With It

Twitter's new verification system shook Eli Lilly — leading LLY stock to skid Friday — after a fake account claimed "insulin is free now."

Investors Business Daily

Biogen tabs veteran pharma leader Viehbacher as next CEO

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

The Independent UK

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

3 Stocks That Are Great for Passive Income Investors

Though the U.S. economy bounced back after shrinking in the first half of the year, falling consumer spending and the rate hikes to tame high inflation might lead the economy into a recession. Hence, investors looking for passive income could invest in fundamentally sound dividend-paying stocks Pfizer (PFE), Sanofi (SNY),…

StockNews.com

Sanofi Hikes Its Profit Outlook Despite Hefty $1.6 Billion Write-Down

Sanofi stock jumped Friday after the company reported better-than-expected third-quarter profit, leading to a guidance boost.

Investors Business Daily

Dismay as key cholera vaccine is discontinued

Exclusive: halt to production of Shanchol vaccine alarms WHO amid ‘unprecedented’ global outbreaks

The Guardian - UK

Strangers save tot's life with supply of drugs hit by Ukraine war

Kind strangers have been donating dioralyte to help save an epileptic child after 'national shortage'

Wales Online

Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash…

Wall Street Journal

Benzinga

Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug

Sanofi's run of bad luck continued Wednesday after the company scrapped a failed breast cancer drug, leading Sanofi stock to crumble.

Investors Business Daily

Benzinga Before The Bell: More Amazon Workers Join Union Over Pay and Work Conditions, UK Inflation Highest In 40 Years, Sole Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand And Other Top Financial Stories Wednesday, August 17

CNBC BlackRock To Pledge A$1B In Australian Battery Storage Assets – Report

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Financial Times

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Benzinga

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Investors Business Daily

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms

Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac.

Investors Business Daily

Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall

Sanofi stock ended flat Thursday despite lifting its profit guidance after blockbuster eczema drug Dupixent topped views.

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Drugmakers are slow to prove medicines that got a fast track to market really work

Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs.

Radio France Internationale

Top French companies pay zero tax, despite year of record profits

The weekly magazine L'Obs is pleased to report that the leading French businesses made record profits in 2021, while the rest of us were cowering in fear of the coronavirus. But did they all pay reasonable taxes in France on those record earnings? L'Obs asked them just that.

Benzinga

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

How Is The Market Feeling About Sanofi?

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of all regular shares that are available for trading.

Investors Business Daily

Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold

Sanofi stock crumbled Thursday after the FDA slapped two of its final-phase studies with a hold, citing safety concerns.

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

1 … 5 6 7 8

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.